An Open-Label Tolerability and Efficacy Study of ZYN002 (Cannabidiol) Administered as a Transdermal Gel to Children and Adolescents with 22q11.2 Deletion Syndrome (INSPIRE)

Helen Heusser1, Jonathan Cohen2, Carolines Buchanan1, Carol O’Neill3, Terri Sebren4, Stephen O’Donnell5

1Centre for Clinical Trials in Rare Neurodevelopmental Disorders, Children’s Health Queensland Hospital and Health Services, South Brisbane, Queensland, AU; 2Genetics Clinic Australia, North Caulfield, Victoria, AU; 3Greenwood Genetic Center, Greenville, SC, USA; 4Zynera Pharmaceuticals, Devon, PA, USA.

BACKGROUND: 22q11.2 DELETION SYNDROME

• 22q11.2 deletion syndrome (22q) is the second most common chromosomal disorder after Down syndrome.
• 22q occurs in 1 in 3000 to 1 in 6000 live births.
• The deletion of genes such as TBX5 may be responsible for characteristic signs (such as heart defects, a cleft palate, distinctive facial features, hearing loss, and low calcium levels) and behavioral problems.
• Children with 22q are at increased risk for several psychiatric disorders, including anxiety, social withdrawal, attention-deficit hyperactivity disorder (ADHD), cognitive impairment, autism spectrum disorder (ASD), and mood disorders, as well as 500 mg psychotic disorders and schizophrenia (adolescence/adulthood).

• Approximately 40% of these children suffer from some type of anxiety disorder.
• Specific phobias are most common, followed by generalized anxiety disorder, separation anxiety, and obsessive-compulsive disorder.
• Early negative experience has been shown to increase the risk of anxiety and is associated with atypical development of the physiological stress response.
• Serious medical complications, such as congenital heart disease, feeding difficulties, and multiple surgeries or hospitalizations, may also predispose some children to anxiety disorders due to stressors associated with repeated medical procedures or poor sense of control over one’s body.
• The presence of anxiety symptoms in children with 22q is negatively correlated with adaptive function and impacts everyday living skills.

BACKGROUND: CANNABIDOL AND ZYN002

• Disruption in the endocannabinoid system (ECS) is one of the proposed mechanisms underlying symptoms affecting children with neurodevelopmental disorders.
• Cannabidiol acts as a negative allosteric modulator at presynaptic type 1 cannabinoid receptors.
• Cannabidiol has also shown activity at serotonin 5HT1a, gamma-aminobutyric acid A, and dopamine D2 and D3 receptors.
• ZYN002 is a pharmaceutically produced (not-plant-derived) cannabidiol transdermal gel in clinical development for the treatment of behavioral symptoms associated with 22q, Fragile X syndrome, FXS, and ASD.
• ZYN002 does not contain delta-9-tetrahydrocannabinol (THC) and avoids cannabidiol in the stomach due to transdermal application.

WHY STUDY ZYN002 IN 22q?

• Anxiety and a constellation of behavioral symptoms are similar between 22q, FXS, and ASD.
• ZYN002 has been shown to have potential benefit in FXS and ASD.
• Dysfunction in the ECS may be present in all 3 disorders.
• ZYN002 does not contain THC. THC may increase the risk for schizophrenia, and should be avoided in individuals with 22q since they are at increased risk of schizophrenia.

METHODS

• 3 sites: 2 in Australia and 1 in the United States.
• Children and adolescents ages 4 through 17 with genetically confirmed 22q also have the following:
  • Pediatric Anxiety Rating Scale-Revised (PARS-R) score of ≥10 at Screening and Visit 2 (Day 1)
  • Clinical Global Impression-Severity (CGI-S) score of ≥4 at Screening and Visit 2 (Day 1)
• Primary outcome measure: Safety and tolerability
• Secondary outcome measures to assess efficacy:
  • PARS-R
  • Anxiety, Depression, and Mood Scale (ADAMS)
  • Afferent Behavior Checklist-Community (ABC-C)
  • Clinical Global Impression-Improvement (CGI-I)
• Qualitative Caregiver Reported Behavioral Problems Survey
• Patients received ZYN002 250 mg (weight ≤35 kg) or 500 mg (weight >35 kg) daily, in divided doses every 12 hours, for 14 weeks as an add-on to standard-of-care medications.
• At Week 6, if the patient had less than a 25% improvement from baseline in the ABC-C imitability subscale, the investigator could increase the dose as follows:
  • Patients who weighed ≤35 kg receiving a total daily dose of 250 mg ZYN002
  • Patients who weighed >35 kg receiving a daily dose of 500 mg ZYN002 could increase the dose to 750 mg/day
• Patients demonstrating improvement were allowed to continue treatment for an additional 24 weeks (Period 2).

RESULTS

20 patients were enrolled; 17 completed 14 periods (Period 1); reasons for the 3 discontinuations included:
• Adverse event unrelated to ZYN002, n=1
• Lost to follow-up, n=1
• Mean age 9.9 years (range 4-15 years); 60% were male
• 53% (8/15 patients) assessed by ASD with Autism Diagnostic Observation Schedule-2 (ADOS-2)
• One patient had an increase in dose from 250 to 500 mg/day at week 6, no patients increased up to 750 mg/day in Period 1.
• At the end of Period 1, statistically significant improvements were seen in all scales of the ADAMS, ABC-C, and PARS-R.

• Clinically Meaningful Improvements in CGI-I
  • 75% of patients were rated by clinicians as “improved,” “much improved,” or “very much improved”
  • 62.5% of patients were rated by clinicians as “much improved” or “very much improved”

CONCLUSIONS

• INSPIRE provides initial evidence suggesting a positive risk-benefit profile for ZYN002 in improving anxiety-related and behavioral symptoms in children and adolescents with 22q when added to a stable standard of care.
• Statistically significant improvements in:
  • PARS-R
  • Total score and all 5 subscales of ADAMS
  • All 5 subscales of ABC-C
• Clinically meaningful improvements in CGI-I ratings
• ZYN002 was well tolerated with a safety profile consistent with other ZYN002 clinical trials.
• These findings warrant further study of ZYN002 in children and adolescents with 22q.

REFERENCES


ACKNOWLEDGEMENTS/DISCLOSURES

Acknowledgments

Editorial medical writing support under the guidance of the author was provided by a-value communications, and was funded by Zynera Pharmaceuticals, Devon, PA, USA.

Disclosures

This presentation is intended to communicate scientific and medical information about data from clinical trials involving ZYN002. This is an experimental treatment that has not been approved by any government regulatory bodies, including the United States Food and Drug Administration (FDA), and has not been determined by the FDA to be safe or effective for any disease or condition. This presentation is not designed or intended to promote the use of ZYN002 by any other Company product in order to impact prescribing.

Helen Heusser, Jonathan Cohen, and Carole Buchanan have received research support from Zynera Pharmaceuticals, and Carlton O’Neill, Terri Sebren, and Stephen O’Donnell are employees of Zynera Pharmaceuticals.

The trial was funded by Zynera Pharmaceuticals.

Presented at the NORD Rare Summit | October 17-18, 2022 | Washington, DC.